New era for treatment in differentiated thyroid cancer
Mené sur 417 patients atteints d'un cancer différencié de la thyroïde, de stade métastatique ou localement avancé et réfractaire à l'iode radioactif, cet essai multicentrique international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du sorafenib
Multikinase inhibitors were introduced into clinical trials for radioactive iodine-refractory differentiated thyroid cancer a decade ago. In The Lancet , Marcia Brose and colleagues report the results of DECISION, the first phase 3 randomised, double-blind, placebo-controlled clinical trial with the multikinase inhibitor sorafenib in differentiated thyroid cancer. On the basis of this landmark trial, sorafenib received an orphan designation by the European Medicine Agency in differentiated thyroid ...
The Lancet , commentaire, 2013